Cardiac Amyloidosis Market Report 2026

The cardiac amyloidosis market size has grown strongly in recent years. It will grow from $5.73 billion in 2025 to $6.24 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to improved recognition of rare cardiac disorders, advancements in echocardiography and mri diagnostics, increasing reporting of amyloidosis cases, expansion of specialist cardiology clinics, growing availability of supportive care options.

The cardiac amyloidosis market size is expected to see strong growth in the next few years. It will grow to $8.71 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of disease-modifying therapies, rising adoption of genetic testing, expansion of specialized amyloidosis treatment centers, growing investment in rare disease research, increasing focus on personalized cardiac therapies. Major trends in the forecast period include increasing focus on early and accurate diagnosis, rising adoption of advanced cardiac imaging techniques, growing use of biomarker-based screening, expansion of targeted therapeutic approaches, enhanced awareness among cardiologists.

The growing geriatric population is expected to drive the expansion of the cardiac amyloidosis market in the coming years. The geriatric population refers to older adults, generally aged 65 and above, who may require specialized healthcare and support due to age-related changes. This population is increasing due to longer life expectancy, improvements in healthcare, and declining birth rates. The rise in the geriatric population contributes to a higher prevalence of cardiac amyloidosis, as aging is a significant risk factor for the accumulation of amyloid proteins in the heart. For example, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the US population aged 65 and older is projected to grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Consequently, the expanding geriatric population is expected to propel the cardiac amyloidosis market.

Key players in the cardiac amyloidosis market are emphasizing technological innovations, such as artificial intelligence (AI)-based software-only diagnostic tools, to enhance early detection and improve clinical outcomes for patients with this underdiagnosed condition. An AI-based, software-only medical device for detecting cardiac amyloidosis is a diagnostic tool that uses artificial intelligence to analyze echocardiographic images and identify disease indicators without the need for additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, obtained FDA clearance for EchoGo Amyloidosis, an AI-driven clinical tool for early detection of cardiac amyloidosis. It is the first device in the FDA's Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. Using AI, EchoGo Amyloidosis examines echocardiograms to detect the disease from a single clip, addressing the urgent need for earlier diagnosis before the condition progresses unnoticed.

In January 2024, Ultromics Ltd., a UK-based health technology company, formed a partnership with Pfizer Inc. to further develop its Echo AI algorithm for the early detection of cardiac amyloidosis. This collaboration is intended to enhance diagnostic accuracy and improve patient outcomes. Pfizer Inc. is a US-based pharmaceutical company that researches, develops, and manufactures medicines for conditions such as cardiac amyloidosis, as well as consumer health care products.

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Neurimmune AG, Attralus Inc., Oncopeptides, SOM Biotech, Amylyx Pharmaceuticals, AstraZeneca plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, CSL Limited.

North America was the largest region in the cardiac amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cardiac amyloidosis market by increasing costs of imported diagnostic reagents, imaging equipment components, pharmaceutical ingredients, and specialized medical devices used in diagnosis and treatment. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported diagnostics and therapies, while Asia-Pacific faces higher costs in expanding treatment access. These tariffs are increasing overall treatment expenses and slowing adoption of advanced diagnostic tools. However, they are also supporting domestic pharmaceutical manufacturing, regional diagnostic development, and increased investment in localized rare disease treatment capabilities.

The cardiac amyloidosis market research report is one of a series of new reports that provides cardiac amyloidosis market statistics, including cardiac amyloidosis industry global market size, regional shares, competitors with a cardiac amyloidosis market share, detailed cardiac amyloidosis market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac amyloidosis industry. This cardiac amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac amyloidosis is a disorder in which abnormal amyloid protein accumulates in the heart tissue, causing stiffening and reduced function. This can lead to heart failure, arrhythmias, and other cardiovascular issues. Early detection and treatment are essential for managing symptoms and slowing the progression of the disease.

The primary types of cardiac amyloidosis are light-chain amyloidosis and transthyretin amyloidosis. Light-chain amyloidosis (AL amyloidosis) occurs when misfolded immunoglobulin light chains form amyloid deposits in organs, including the heart, resulting in dysfunction and potential organ failure. Treatment approaches include chemotherapy, surgery, supportive care, stem cell transplantation, and targeted therapies, with management primarily taking place in hospitals, ambulatory surgical centers, and clinics.

The cardiac amyloidosis market consists of revenues earned by entities by providing services such as early diagnosis through imaging and biomarker testing, medication management, and supportive therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac amyloidosis market also includes sales of diagnostic imaging tools, biomarker testing kits, and disease-modifying therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.